BioMap

Excited to announce that our president, Per Jr. Greisen, will be sharing his expertise on AI for design and engineering of biologics, including de novo design of VHH and computational generation of bispecifics, at #BioLogicSummit this January in San Diego! Join us!

BioMap celebrates David Baker‘s Nobel Prize in Chemistry!🎉 https://lnkd.in/g4TZE-4d His groundbreaking research in protein design has transformed the field, inspiring a new generation of scientists like our President, Per Jr. Greisen, who trained at the Institute for Protein Design, University of Washington. We believe, like Dr. Baker, that proteins hold the key to solving many of today's challenges, from advancing human health to creating a greener economy. We applaud his vision and dedication to scientific advancement. 👏🏻 👏🏻 #NobelPrize #AI4LifeScience #ProteinDesign

AI models like AlphaFold have pushed the boundaries for the structure prediction of single proteins. However, predicting the binding of biotherapeutics, including antibodies (Abs) and VHHs, onto their targets remains a challenging area. Accurate predictions of such interactions will unlock new insights into mechanisms of actions, and potentially lead to better drug design 🧬🔬 To compare the current industry leaders in this space, BioMap and an external lab have tested the accuracy of AlphaFold 3, the new AlphaFold version released by DeepMind, and xTrimoDock, the antibody docking prediction model from BioMap. Preliminary results show that in this dataset, xTrimoDock outperformed AlphaFold 3 consistently at modeling the structure of Abs and VHHs in complex with their target proteins. Contact us to find out more.

BioMap has a team of world-class scientists and engineers that have extensive expertise in AI, biology, bioinformatics and engineering. Our large language life science models enable our partners, collaborators and customers to produce pioneering products that will benefit the world 🌎 🧬 #Bioinformatics #AI #Innovation #Technology #LargeLanguageModels #Biotech

If you’re attending ICML 2024, don’t forget to sign up for the ‘AI for Science - Scaling in AI for Scientific Discovery’ workshop on July 26th, 9:00 a.m. - 5:00 p.m. CEST. Le Song, CTO at BioMap, will be presenting our paper: “Training Compute-Optimal Protein Language Models”. Through extensive training of more than 300 models, this research has uncovered important insights into how model size, training data, and performance are interconnected. Secure your place at the workshop here: https://buff.ly/3S4WPbb #MachineLearning #ML #AI #ArtificialIntelligence #Science #Technology #Innovation #BioMap #ICML

Have you applied to the BioMap BioX program yet? In line with our dedication to fostering tech innovation and accelerating the bio-computing ecosystem globally, BioMap has launched the BioX initiative to accelerate global life sciences development with AI. The program is designed to support the transformation of early-stage R&D into market-ready products and industrialized companies, focusing on pharmaceuticals and health, green technology, industrial innovation, and consumer product innovation. Benefits for successful applicants: - Access to BioMap’s AIGP platform with credits worth over $200,000 - Assistance in connecting with international companies and demand side entities - Access to professional AI, biology, and IT experts, as well as training programs tailored to the needs of startup projects - Access to InnoX's network of signed investors, with investment funds available for evaluated startup projects Submit your application here: https://buff.ly/3VS90sU

BioMap and Porton Advanced have joined forces to usher in a new era of gene therapy with AI-powered adeno-associated virus (AAV) solutions! 🧬   This groundbreaking partnership leverages BioMap's cutting-edge AI models (xTrimoPGLM) with Porton Advanced's expertise in AAV development.   Together, we're revolutionizing AAV vector design, offering: - Innovative AAV library design service: Over 10 serotypes, enhanced transduction efficiency, tissue specificity & immune evasion. - Industry-leading xTrimoAAVViability v1.0 model: Predicts AAV viability with unmatched accuracy, accelerating vector development. - Bespoke AI design services: Tailored model fine-tuning for personalized needs.   This collaboration unlocks new possibilities in gene therapy research! 🔬   Ready to join us in pioneering the future?   Contact us at info@biomap.com to explore how BioMap's AI expertise and Porton Advanced's experience can accelerate your gene therapy project.   #genetherapy #AAV #AI #biotech #partnership #innovation #ArtificialIntelligence #technology Porton Advanced │ Cell & Gene Therapy CDMO/CRO

Don’t forget to apply to the BioMap BioX program! Targeting four key areas — pharmaceuticals and health, green technology, industrial innovation, and consumer product innovation — BioMap will select and support teams from universities and startups, providing technical support and facilitating connections with global companies and investors in the life sciences and bio-computing sectors. Whether you are: - a cutting-edge life sciences researcher exploring the underlying mechanisms of biology through protein perturbations - a protein industry scientist designing new protein products - a drug discovery scientist solving large molecule design challenges with new technologies - or an innovative young entrepreneur using AI to change the world We welcome you to join the initiative! Don’t miss the opportunity to take advantage of BioMap’s 100-Billion parameter large protein language model and platform ecosystem capabilities to support your transition from early-stage research to marketable products and industrial-scale companies. Apply now: https://buff.ly/3VS90sU

BioMap will be attending the International Conference on Machine Learning (ICML) 2024 in Vienna from July 21st-26th. 🇦🇹 We’re looking forward to coming together with academic and industry peers to explore the latest advancements in machine learning and AI. 💡   During the ‘AI for Science - Scaling in AI for Scientific Discovery’ workshop on Friday 26 Jul, 9:00 a.m. - 5:00 p.m. CEST, BioMap’s CTO Le Song will be presenting our latest research on “Training Compute-Optimal Protein Language Models”. This research, which involved extensive training of over 300 models, has yielded significant insights into the relationship between model size, training data, and performance.   The study introduces a novel approach to address the issue of overfitting and performance plateaus in PLMs by utilizing a vast dataset of 194 billion unique tokens from 939 million protein sequences. It reveals distinct scaling laws for both masked language modelling (MLM) and causal language modelling (CLM), demonstrating the effectiveness of transferring knowledge from CLM to MLM through scaling behaviours.   ✅ Sign up for the workshop here: https://lnkd.in/gcAfyWnW   #MachineLearning #ML #AI #ArtificialIntelligence #Science #Technology #Innovation #BioMap #ICML [ICML] Int'l Conference on Machine Learning

High-performing protein prediction models can potentially enable more accurate, efficient, and innovative drug development workflows💊💉 While AlphaFold3 is often considered to be the industry performance benchmark, a new comparison study has demonstrated that there are alternative approaches to the application of AI in protein design that can yield equally impressive or even superior performance. The study compared xTrimoDock, the antibody docking prediction model from BioMap, to Google DeepMind’s new AlphaFold 3. Preliminary results have shown that xTrimo outperforms AlphaFold 3 in its accuracy in predicting the structure and binding of selected proteins, including antibodies and other biotherapeutics, with their targets ⚙️🧬 Contact us to learn more.